Sunday, April.22.2018
TOP NEWS
|
REGULATORY
|
BUSINESS
|
ORGANIZATION
|
ACADEMIA
Home
>
Sitemap
Site Top
News
Latest News
Photos
Categories
Regulatory
Business
Organization
Academia
Others
Corporate Profile
Site Policy
Privacy Policy
Terms Of Use
Link Policy
Inquiry
Contents
Commentary
Lexicon
The Column
With Drug Price Cuts Done, MHLW Now Running Ministry-Wide Initiative to Shave Prescriptions
G1/G2 Rule:
G1/G2ルール
It Is Thumbs Up for Cell Therapy in Japan
No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)
Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
1.
AZ’s PD-L1 Inhibitor Durvalumab Up for M...
2.
Tecentriq Now in PD-1/L1 NSCLC Showdown,...
3.
Tecentriq to Provide New Option for NSCL...
4.
PhRMA Chief Warns of Serious Implication...
5.
Pharma Leaders Air Grievances on Pricing...
1.
AZ’s PD-L1 Inhibitor Durvalumab Up for M...
2.
Single Generic Pricing Rule Will Acceler...
3.
Lilly Japan Sales Up 7% in 2017, Upbeat ...
4.
Opdivo Faces 23.8% Price Cut as Slew of ...
5.
PhRMA Chief Warns of Serious Implication...